The feasibility of fertility-sparing treatment of young patients with recurrent endometrial cancer
- Authors: Babaeva N.A.1, Antonova I.B.1, Ivashina S.V.1, Aleshikova O.I.1, Lyustik A.V.1, Ashrafyan L.A.2,1
-
Affiliations:
- Russian Scientific Center of Roentgeno-Radiology of Minzdrav of Russia
- V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia
- Issue: No 1S (2020): Supplement
- Pages: 130-135
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248799
- DOI: https://doi.org/10.18565/aig.2020.1suppl.130-136
- ID: 248799
Cite item
Open Access
Access granted
Abstract
Endometrial cancer is the most prevalent gynecological cancer. About 2.9-14.4% of patients with endometrial cancer are aged below 40, and the incidence of cancer in this age group is on the rise. Most cases of endometrial cancer in women of this age are diagnosed at an early stage with no myometrial invasion and lymph node involvement. Therefore, such patients have a high cure rate, and for them, a quality of life is an extremely important outcome after treatment. Fertility preservation is one of the most important issues of long-term quality of life of cancer survivors of childbearing age. Presentation A 33-year-old woman T. first presented with complaints of heavy menstrual bleeding. Her diagnostic evaluation included hysteroscopy and fractional curettage with a sampling of both the endometrial and the endocervical mucosa. Histopathological study revealed highly differentiated endometrial adenocarcinoma. Taking into account the patient’s age, nulliparous status and her desire to preserve fertility, conservative treatment was initiated. Conclusion Conservative fertility-sparing treatment is highly effective in young patients with stage IA and G1 primary and recurrent endometrial adenocarcinoma. This treatment modality is safe and effective when applied to patients who met indications and most likely to comply with planned therapy.
Full Text
About the authors
Nataliya A. Babaeva
Russian Scientific Center of Roentgeno-Radiology of Minzdrav of Russia
Email: natbabaeva@yandex.ru
Irina B. Antonova
Russian Scientific Center of Roentgeno-Radiology of Minzdrav of Russia
Email: iran24@yandex.ru
Svetlana V. Ivashina
Russian Scientific Center of Roentgeno-Radiology of Minzdrav of Russia
Email: s.ivashina@bk.ru
Olga I. Aleshikova
Russian Scientific Center of Roentgeno-Radiology of Minzdrav of Russia
Email: olga.aleshikova@gmail.com
Anna Valeryevna Lyustik
Russian Scientific Center of Roentgeno-Radiology of Minzdrav of Russia
Levon A. Ashrafyan
V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia; Russian Scientific Center of Roentgeno-Radiology of Minzdrav of Russia
Email: levaa2004@yahoo.com
References
- Colombo N., Creutzberg C., Amant F. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(1): 16-41. doi: https://doi.org/10.1093/annonc/mdv484
- Каприн А.Д., Старинский В.В., Петрова Г.В., ред. Состояние онкологической помощи населению России в 2017 году. М., 2018. 234 с.
- Lancaster J.M., Powell C.B., Chen L.M., Richardson D.L. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015; 136: 3-7. doi: 10.1016/j. ygyno.2014.09.009
- Новикова О.В., Новикова Е.Г., Волченко Н.Н., et al. Лечение рецидивов атипической гиперплазии и начального рака эндометрия после самостоятельной гормонотерапии. Акушерство и гинекология: новости, мнения, обучение. 2018; 1: 68-76.
- Пронин С.М., О.В. Новикова, Андреева Ю.Ю. Применение рилизинг-систем и агонистов гонадотропин-рилизинг-гормона в лечении атипической гиперплазии и начального рака эндометрия. Онкология. Журнал им. П.А. Герцена. 2013; 1: 40-3.
- Gallos I.D., Krishan P., Shehmar M., Ganesan R., Gupta J.K. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with longterm follow-up. Hum. Reprod. 2013; 28: 1231-6. doi: 10.1093/humrep/det049
- Park J.Y., Kim D.Y., Kim J.H., Kim Y.M., Kim K.R., Kim Y.T., et al. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002) Eur. J. Cancer. 2013; 49: 868-74. doi: 10.1016/j.ejca.2012.09.017
- Nevadunsky N.S., Van Arsdale, A. Strickler H.D., Moadel A., Kaur G. Frimer M., et al. Metformin use and endometrial cancer survival. Gynecol Oncol. 2014; 132: 236-40 doi: 10.1016/j.ygyno.2013.10.026.
- Wei J., Zhang W., Feng L., Gao W. Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasia: a metaanalysis and systematic review. Medicine (Baltimore). 2017; 96(37): e8034. doi: 10.1097/MD.0000000000008034
- SGO Clinical Practice Endometrial Cancer Working Group, Burke W.M., Orr J., Leitao M., Salom E., Gehrig P., Olawaiye AB., Brewer M., Boruta D., Herzog T.J., Shahin F.A.; Society of Gynecologic Oncology Clinical Practice Committee. Endometrial cancer: A review and current management strategies : part II. Gynecol Oncol. 2014;134(2): 393-402. doi: 10.1016/j.ygyno.2014.06.00
- Yamagami W., Susumu N., Makabe T. Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility? J. Gynecol Oncol. 2018; 29(2): e21. doi: 10.3802/jgo.2018.29.e21
- Koh W.J., Abu-Rustum N.R., Bean S., Bradley K., et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr Canc Netw. 2018; 16(2): 170-99. doi: 10.6004/jnccn.2018.0006.
Supplementary files
